Exploring how psychological stress affects treatment outcomes in gastric cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational cohort study aims to investigate the relationship between psychological stress and the efficacy of treatments for gastric cancer. Participants will include patients diagnosed with primary adenocarcinoma of gastric cancer who have undergone surgery, chemotherapy, and immune checkpoint inhibitors. The study will assess the psychological stress status of these patients to determine its impact on their treatment outcomes and prognosis. By analyzing these associations, the study seeks to provide insights into how stress may influence recovery and survival rates in gastric cancer patients.

Why it matters

Who can join: the full rules

Cohort 1

Inclusion Criteria:

1. Lower age limit of research subjects 18 years old and upper age limit of 80 years old, ECOG (ECOG score standard) performance status of 0 or 1
2. Be proven to be primary adenocarcinoma of gastric cancer and staged II-III by pathological evidences
3. R0 gastrectomy with D2 lymphadenectomy
4. Receiving adjuvant chemotherapy

Exclusion Criteria:

1. History of chemotherapy, radiotherapy, immunotherapy or target therapy
2. Multiple primary tumors
3. Suffering from other serious diseases, including cardiovascular, respiratory, kidney, or liver disease, complicated by poorly controlled hypertension, diabetes, mental disorders or diseases
4. Unavailable for R0 resection and D2 lymph node dissection.
5. Patients with stage IV gastric cancer

Cohort 2

Inclusion Criteria:

1. Lower age limit of research subjects 18 years old and upper age limit of 80 years old, ECOG (ECOG score standard) performance status of 0 or 1
2. Be proven to be primary adenocarcinoma of gastric cancer and staged III-IV by pathological evidences
3. Receiving gastrectomy
4. Receiving preoperative chemotherapy

Exclusion Criteria:

1. Unavailable for chemotherapy, radiotherapy, immunotherapy or target therapy
2. Multiple primary tumors
3. Suffering from other serious diseases, including cardiovascular, respiratory, kidney, or liver disease, complicated by poorly controlled hypertension, diabetes, mental disorders or diseases
4. Unavailable for gastrectomy

Cohort 2

Inclusion Criteria:

1. Lower age limit of research subjects 18 years old and upper age limit of 80 years old, ECOG (ECOG score standard) performance status of 0 or 1
2. Be proven to be primary adenocarcinoma of gastric cancer and staged IV by pathological evidences
3. Unavailable for gastrectomy
4. Presence of at least one measurable lesion according to the Response Evaluation Criteria in Solid Tumors version 1.1

Exclusion Criteria:

1. Unavailable for chemotherapy, radiotherapy, immunotherapy or target therapy
2. Multiple primary tumors
3. Suffering from other serious diseases, including cardiovascular, respiratory, kidney, or liver disease, complicated by poorly controlled hypertension, diabetes, mental disorders or diseases

Where it's running

• Fudan University Shanghai Cancer Center
  Shanghai, Shanghai Municipality, China Recruiting

Study contacts

• Study coordinator: Jing Guo, MD
• Email: gjsysu@126.com
• Phone: 86-02164175590

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Robotic versus laparoscopic radical surgery for locally advanced stomach and gastroesophageal junction cancer

  This trial will test whether robotic gastrectomy is as effective as — and safer than — laparoscopic gastrectomy for adults aged 18–74 with locally advanced stomach or gastroesophageal junction cancer.

  Recruiting Southwest Hospital, China · Chongqing, Chongqing Municipality and 1 other locations · NCT06791538

• Treatment of locally advanced gastric cancer with Tislelizumab and chemotherapy

  This study is testing if a new treatment combining Tislelizumab and chemotherapy can help people with locally advanced gastric cancer live longer and have fewer problems after treatment.

  Recruiting Southwest Hospital, China · Chongqing, Chongqing Municipality and 1 other locations · NCT06760858

• Predicting treatment response in gastric cancer using immune markers

  This study is trying to find out if certain immune markers in the blood can help doctors predict how well advanced gastric cancer patients will respond to chemotherapy and immunotherapy.

  Recruiting Shanghai Zhongshan Hospital · Xuhui District, Shanghai Municipality · NCT06662110

• Oral Paclitaxel Plus Fruquintinib as Second-Line Treatment in Advanced Gastric/GEJ Cancer

  This trial tests whether taking an oral paclitaxel solution together with fruquintinib, chosen by the investigator, can help adults with advanced or metastatic stomach or gastroesophageal junction cancer after first-line therapy.

  Recruiting at 15 sites Harbin Medical University · Fuzhou, Fujian and 14 other locations · NCT07552402

• Sintilimab plus SOX chemotherapy versus SOX alone after surgery for stomach or gastroesophageal junction adenocarcinoma

  This trial will test whether adding sintilimab to SOX chemotherapy after surgery helps people with stage IIIC or dMMR/MSI‑H stage IIIA/IIIB stomach or gastroesophageal junction cancer stay disease‑free longer.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT07492615

• Neoadjuvant cadonilimab plus perioperative SOX for diffuse or mixed locally advanced stomach/GEJ cancer

  This will test whether adding cadonilimab to perioperative SOX chemotherapy helps people with diffuse or mixed locally advanced stomach or gastroesophageal junction adenocarcinoma.

  Recruiting at 4 sites Phase 3 Lanzhou University Second Hospital · Lanzhou, Gansu and 3 other locations · NCT06949033

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.